메뉴 건너뛰기




Volumn 19, Issue 26, 2013, Pages 4701-4713

Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitors

Author keywords

And zinc binding group; Cancer; Docking; MMP 13; MMP 2; MMP 3; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ABT 518; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYDROXAMIC ACID; ILOMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; RS 113456; SC 77774; SM 25453; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT; ZINC BINDING PROTEIN; ZINC ION;

EID: 84881350248     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319260004     Document Type: Article
Times cited : (7)

References (82)
  • 1
    • 0028609624 scopus 로고
    • Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
    • Weinstat-Saslow DL, Zabrenetzky VS, vanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11.
    • (1994) Cancer Res , vol.54 , pp. 6504-6511
    • Weinstat-Saslow, D.L.1    Zabrenetzky, V.S.2    vanHoutte, K.3    Frazier, W.A.4    Roberts, D.D.5    Steeg, P.S.6
  • 2
    • 0001651169 scopus 로고    scopus 로고
    • Design and therapeutic application of matrix metalloproteinase inhibitors
    • Whittaker M, Floyd CD, Bowen P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99: 2735-76.
    • (1999) Chem Rev , vol.99 , pp. 2735-2776
    • Whittaker, M.1    Floyd, C.D.2    Bowen, P.3    Gearing, A.J.H.4
  • 3
    • 77950931419 scopus 로고    scopus 로고
    • Matrix metalloproteinases: Regulators of the tumor microenviroment
    • Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenviroment. Cell 2010; 141: 52-67.
    • (2010) Cell , vol.141 , pp. 52-67
    • Kessenbrock, K.1    Plaks, V.2    Werb, Z.3
  • 4
    • 38049177345 scopus 로고    scopus 로고
    • Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis
    • Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-7.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 20262-20267
    • Ardi, V.C.1    Kupriyanova, T.A.2    Deryugina, E.I.3    Quigley, J.P.4
  • 5
    • 79955698736 scopus 로고    scopus 로고
    • Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: A review
    • Yadav RK, Gupta SP, Sharma PK, Patil VM. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. Curr Med Chem 2011; 18:1704-22.
    • (2011) Curr Med Chem , vol.18 , pp. 1704-1722
    • Yadav, R.K.1    Gupta, S.P.2    Sharma, P.K.3    Patil, V.M.4
  • 6
    • 34547398983 scopus 로고    scopus 로고
    • Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors
    • Gupta SP. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. Chem Rev 2007; 107: 3042-87.
    • (2007) Chem Rev , vol.107 , pp. 3042-3087
    • Gupta, S.P.1
  • 7
    • 47349084576 scopus 로고    scopus 로고
    • Progress in the development of matrix metalloproteinase inhibitors
    • Tu G, Xu W, Huang H, Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 2008; 15: 1388-95.
    • (2008) Curr Med Chem , vol.15 , pp. 1388-1395
    • Tu, G.1    Xu, W.2    Huang, H.3    Li, S.4
  • 8
    • 20044388325 scopus 로고    scopus 로고
    • Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer
    • Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005; 23: 842-9.
    • (2005) J Clin Oncol , vol.23 , pp. 842-849
    • Bissett, D.1    O'Byrne, K.J.2    von Pawel, J.3
  • 9
    • 0037975559 scopus 로고    scopus 로고
    • Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats
    • Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003; 48: 1742-9.
    • (2003) Arthritis Rheum , vol.48 , pp. 1742-1749
    • Renkiewicz, R.1    Qiu, L.2    Lesch, C.3
  • 10
    • 0031716672 scopus 로고    scopus 로고
    • Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
    • Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998; 80(5): 907-8.
    • (1998) J Bone Joint Surg Br , vol.80 , Issue.5 , pp. 907-908
    • Hutchinson, J.W.1    Tierney, G.M.2    Parsons, S.L.3    Davis, T.R.4
  • 11
    • 77955652686 scopus 로고    scopus 로고
    • Biaryl substituted hydantoin compounds as TACE inhibitors
    • Yu W, Tong L, Kim SH, et al. Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett. 2010; 20(17): 5286-9.
    • (2010) Bioorg Med Chem Lett. , vol.20 , Issue.17 , pp. 5286-5289
    • Yu, W.1    Tong, L.2    Kim, S.H.3
  • 12
    • 0037112183 scopus 로고    scopus 로고
    • Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer
    • Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434-9.
    • (2002) J Clin Oncol , vol.20 , Issue.22 , pp. 4434-4439
    • Shepherd, F.A.1    Giaccone, G.2    Seymour, L.3
  • 13
    • 14044274265 scopus 로고    scopus 로고
    • Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies
    • Rao BG. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005; 11(3): 295-322.
    • (2005) Curr Pharm Des , vol.11 , Issue.3 , pp. 295-322
    • Rao, B.G.1
  • 14
    • 4444341426 scopus 로고    scopus 로고
    • The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories
    • Wada CK. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 2004; 4(12): 1255-67.
    • (2004) Curr Top Med Chem , vol.4 , Issue.12 , pp. 1255-1267
    • Wada, C.K.1
  • 15
    • 33745963397 scopus 로고    scopus 로고
    • A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study
    • Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006; 102(2): 300-8.
    • (2006) Gynecol Oncol , vol.102 , Issue.2 , pp. 300-308
    • Hirte, H.1    Vergote, I.B.2    Jeffrey, J.R.3
  • 16
    • 0043238937 scopus 로고    scopus 로고
    • Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model
    • Nozaki S, Sissons S, Chien DS, Sledge GW Jr. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clin Exp Metastasis 2003; 20(5): 407-12.
    • (2003) Clin Exp Metastasis , vol.20 , Issue.5 , pp. 407-412
    • Nozaki, S.1    Sissons, S.2    Chien, D.S.3    Sledge Jr., G.W.4
  • 17
    • 23644441594 scopus 로고    scopus 로고
    • Identification of potent and selective MMP-13 inhibitors
    • Wu J, Rush TS III, Hotchandani R, et al. Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005; 15(18): 4105-9.
    • (2005) Bioorg Med Chem Lett , vol.15 , Issue.18 , pp. 4105-4109
    • Wu, J.1    Rush III, T.S.2    Hotchandani, R.3
  • 18
    • 0034635966 scopus 로고    scopus 로고
    • Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
    • Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97(8): 4052-7.
    • (2000) Proc Natl Acad Sci USA , vol.97 , Issue.8 , pp. 4052-4057
    • Zhou, Z.1    Apte, S.S.2    Soininen, R.3
  • 19
    • 80052032038 scopus 로고    scopus 로고
    • Inflammation in osteoarthritis
    • Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23(5): 471-8.
    • (2011) Curr Opin Rheumatol , vol.23 , Issue.5 , pp. 471-478
    • Goldring, M.B.1    Otero, M.2
  • 20
  • 21
    • 0029666453 scopus 로고    scopus 로고
    • Understanding the P1' specificity of the matrix metalloproteinases: Effect of S1' pocket mutations in matrilysin and stromelysin-1
    • Welch AR, Holman CM, Huber M, Brenner MC, Browner MF, Van Wart HE. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996; 35(31): 10103-9.
    • (1996) Biochemistry , vol.35 , Issue.31 , pp. 10103-10109
    • Welch, A.R.1    Holman, C.M.2    Huber, M.3    Brenner, M.C.4    Browner, M.F.5    Van Wart, H.E.6
  • 22
    • 0029030448 scopus 로고
    • Matrilysin-inhibitor complexes: Common themes among metalloproteases
    • Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995; 34(20): 6602-10.
    • (1995) Biochemistry , vol.34 , Issue.20 , pp. 6602-6610
    • Browner, M.F.1    Smith, W.W.2    Castelhano, A.L.3
  • 23
    • 0033048045 scopus 로고    scopus 로고
    • Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors
    • Lovejoy B, Welch AR, Carr S, et al. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999; 6(3): 217-21.
    • (1999) Nat Struct Biol , vol.6 , Issue.3 , pp. 217-221
    • Lovejoy, B.1    Welch, A.R.2    Carr, S.3
  • 24
    • 34447617899 scopus 로고    scopus 로고
    • Structure-based design of TACE selective inhibitors: Manipulations in the S1'-S3' pocket
    • Huang A, Joseph-McCarthy D, Lovering F, et al. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. Bioorg Med Chem 2007; 15(18): 6170-81.
    • (2007) Bioorg Med Chem , vol.15 , Issue.18 , pp. 6170-6181
    • Huang, A.1    Joseph-McCarthy, D.2    Lovering, F.3
  • 25
    • 33646053826 scopus 로고    scopus 로고
    • Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453
    • Kohno T, Hochigai H, Yamashita E, Tsukihara T, Kanaoka M. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453. Biochem Biophys Res Commun 2006; 344(1): 315-22.
    • (2006) Biochem Biophys Res Commun , vol.344 , Issue.1 , pp. 315-322
    • Kohno, T.1    Hochigai, H.2    Yamashita, E.3    Tsukihara, T.4    Kanaoka, M.5
  • 26
    • 77954219616 scopus 로고    scopus 로고
    • Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alphasulfone hydroxamates
    • Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alphasulfone hydroxamates. Bioorg Med Chem Lett 2010; 20(12): 3557-60.
    • (2010) Bioorg Med Chem Lett , vol.20 , Issue.12 , pp. 3557-3560
    • Kolodziej, S.A.1    Hockerman, S.L.2    Boehm, T.L.3
  • 27
    • 77956763130 scopus 로고    scopus 로고
    • Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
    • Becker DP, Barta TE, Bedell LJ, et al. Orally active MMP-1 sparing a-tetrahydropyranyl and a-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem 2010; 53(18): 6653-80.
    • (2010) J Med Chem , vol.53 , Issue.18 , pp. 6653-6680
    • Becker, D.P.1    Barta, T.E.2    Bedell, L.J.3
  • 28
    • 68549135187 scopus 로고    scopus 로고
    • N-O-isopropyl sulfonamido-based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis
    • Nuti E, Casalini F, Avramova SI, et al. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem 2009; 52(15): 4757-73.
    • (2009) J Med Chem , vol.52 , Issue.15 , pp. 4757-4773
    • Nuti, E.1    Casalini, F.2    Avramova, S.I.3
  • 29
    • 0035935193 scopus 로고    scopus 로고
    • Alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1
    • Becker DP, Barta TE, Bedell L, et al. Alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1. Bioorg Med Chem Lett 2001; 11(20): 2719-22.
    • (2001) Bioorg Med Chem Lett , vol.11 , Issue.20 , pp. 2719-2722
    • Becker, D.P.1    Barta, T.E.2    Bedell, L.3
  • 30
    • 39749124201 scopus 로고    scopus 로고
    • Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
    • Li JJ, Nahra J, Johnson AR, et al. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. J Med Chem 2008; 51(4): 835-41.
    • (2008) J Med Chem , vol.51 , Issue.4 , pp. 835-841
    • Li, J.J.1    Nahra, J.2    Johnson, A.R.3
  • 31
    • 67651123042 scopus 로고    scopus 로고
    • 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding
    • Li W, Hu Y, Li J, et al. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. Bioorg Med Chem Lett 2009; 19(16): 4546-50.
    • (2009) Bioorg Med Chem Lett , vol.19 , Issue.16 , pp. 4546-4550
    • Li, W.1    Hu, Y.2    Li, J.3
  • 32
    • 66749184678 scopus 로고    scopus 로고
    • Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13
    • Monovich LG, Tommasi RA, Fujimoto RA, et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J Med Chem 2009; 52(11): 3523-38.
    • (2009) J Med Chem , vol.52 , Issue.11 , pp. 3523-3538
    • Monovich, L.G.1    Tommasi, R.A.2    Fujimoto, R.A.3
  • 33
    • 34948864524 scopus 로고    scopus 로고
    • Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects
    • Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282(38): 27781-91.
    • (2007) J Biol Chem , vol.282 , Issue.38 , pp. 27781-27791
    • Johnson, A.R.1    Pavlovsky, A.G.2    Ortwine, D.F.3
  • 34
    • 67650045889 scopus 로고    scopus 로고
    • A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models
    • Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009; 60(7): 2008-18.
    • (2009) Arthritis Rheum , vol.60 , Issue.7 , pp. 2008-2018
    • Baragi, V.M.1    Becher, G.2    Bendele, A.M.3
  • 35
    • 77955661111 scopus 로고    scopus 로고
    • SAR studies of non-zincchelating MMP-13 inhibitors: Improving selectivity and metabolic stability
    • Gao DA, Xiong Z, Heim-Riether A, et al. SAR studies of non-zincchelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010; 20(17): 5039-43.
    • (2010) Bioorg Med Chem Lett , vol.20 , Issue.17 , pp. 5039-5043
    • Gao, D.A.1    Xiong, Z.2    Heim-Riether, A.3
  • 36
    • 68949125078 scopus 로고    scopus 로고
    • Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors
    • Heim-Riether A, Taylor SJ, Liang S, et al. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg Med Chem Lett 2009; 19(18): 5321-4.
    • (2009) Bioorg Med Chem Lett , vol.19 , Issue.18 , pp. 5321-5324
    • Heim-Riether, A.1    Taylor, S.J.2    Liang, S.3
  • 37
    • 80255136352 scopus 로고    scopus 로고
    • Identification of novel, exositebinding matrix metalloproteinase-13 inhibitor scaffolds
    • Roth J, Minond D, Darout E, et al. Identification of novel, exositebinding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett 2011; 21(23): 7180-4.
    • (2011) Bioorg Med Chem Lett , vol.21 , Issue.23 , pp. 7180-7184
    • Roth, J.1    Minond, D.2    Darout, E.3
  • 38
    • 20144369218 scopus 로고    scopus 로고
    • Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14
    • Blagg JA, Noe MC, Wolf-Gouveia LA, et al. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005; 15(7): 1807-10.
    • (2005) Bioorg Med Chem Lett , vol.15 , Issue.7 , pp. 1807-1810
    • Blagg, J.A.1    Noe, M.C.2    Wolf-Gouveia, L.A.3
  • 39
    • 84856400550 scopus 로고    scopus 로고
    • Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis
    • Cege C, Bao B, Bluhm H, et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem 2012; 55 (2): 709-16.
    • (2012) J Med Chem , vol.55 , Issue.2 , pp. 709-716
    • Cege, C.1    Bao, B.2    Bluhm, H.3
  • 40
    • 82555187389 scopus 로고    scopus 로고
    • Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13
    • Taylor SJ, Abeywardane A, Liang S, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem 2011; 54(23): 8174-87.
    • (2011) J Med Chem , vol.54 , Issue.23 , pp. 8174-8187
    • Taylor, S.J.1    Abeywardane, A.2    Liang, S.3
  • 41
    • 84055221868 scopus 로고    scopus 로고
    • Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases
    • Marques SM, Tuccinardi T, Nuti E, et al. Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases J Med Chem 2011; 54 (24): 8289-98.
    • (2011) J Med Chem , vol.54 , Issue.24 , pp. 8289-8298
    • Marques, S.M.1    Tuccinardi, T.2    Nuti, E.3
  • 42
    • 78650424066 scopus 로고    scopus 로고
    • Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
    • Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278(1): 16-27.
    • (2011) FEBS J , vol.278 , Issue.1 , pp. 16-27
    • Gialeli, C.1    Theocharis, A.D.2    Karamanos, N.K.3
  • 43
    • 10744223801 scopus 로고    scopus 로고
    • Physiological levels of tumstatin, a fragment of collagen IV 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via V3 integrin
    • Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via V3 integrin. Cancer Cell 2003; 3: 589-601.
    • (2003) Cancer Cell , vol.3 , pp. 589-601
    • Hamano, Y.1    Zeisberg, M.2    Sugimoto, H.3
  • 44
    • 0000391746 scopus 로고    scopus 로고
    • Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    • Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
    • (2000) Nat Cell Biol , vol.2 , pp. 737-744
    • Bergers, G.1    Brekken, R.2    McMahon, G.3
  • 45
    • 38049177345 scopus 로고    scopus 로고
    • Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis
    • Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-67.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 20262-20267
    • Ardi, V.C.1    Kupriyanova, T.A.2    Deryugina, E.I.3    Quigley, J.P.4
  • 46
    • 0029829166 scopus 로고    scopus 로고
    • Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells
    • Festuccia C, Bologna M, Vicentini C, et al. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996; 69(5): 386-93.
    • (1996) Int J Cancer , vol.69 , Issue.5 , pp. 386-393
    • Festuccia, C.1    Bologna, M.2    Vicentini, C.3
  • 47
    • 58149348622 scopus 로고    scopus 로고
    • Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression
    • Castellano G, Malaponte G, Mazzarino MC, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008; 14(22): 7470-80.
    • (2008) Clin Cancer Res , vol.14 , Issue.22 , pp. 7470-7480
    • Castellano, G.1    Malaponte, G.2    Mazzarino, M.C.3
  • 48
    • 1042290312 scopus 로고    scopus 로고
    • A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node positive breast carcinoma
    • Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node positive breast carcinoma. Clin Cancer Res 2004; 10: 1057-63.
    • (2004) Clin Cancer Res , vol.10 , pp. 1057-1063
    • Leppa, S.1    Saarto, T.2    Vehmanen, L.3    Blomqvist, C.4    Elomaa, I.5
  • 49
    • 79958782153 scopus 로고    scopus 로고
    • Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression
    • Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression. Clin Biochem 2011; 44(10-11): 869-72.
    • (2011) Clin Biochem , vol.44 , Issue.10-11 , pp. 869-872
    • Patel, S.1    Sumitra, G.2    Koner, B.C.3    Saxena, A.4
  • 50
    • 0032031861 scopus 로고    scopus 로고
    • Reduced angiogenesis and tumor progression in gelatinase Adeficient mice
    • Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase Adeficient mice. Cancer Res 1998; 58(5): 1048-51.
    • (1998) Cancer Res , vol.58 , Issue.5 , pp. 1048-1051
    • Itoh, T.1    Tanioka, M.2    Yoshida, H.3    Yoshioka, T.4    Nishimoto, H.5    Itohara, S.6
  • 51
    • 0034628453 scopus 로고    scopus 로고
    • Design and synthesis of piperazinebased matrix metalloproteinase inhibitors
    • Cheng M, De B, Pikul S, et al. Design and synthesis of piperazinebased matrix metalloproteinase inhibitors. J Med Chem 2000; 43(3): 369-80.
    • (2000) J Med Chem , vol.43 , Issue.3 , pp. 369-380
    • Cheng, M.1    De, B.2    Pikul, S.3
  • 52
    • 16944365890 scopus 로고    scopus 로고
    • Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR
    • Hajduk PJ, Sheppard G, Nettesheim DG, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 1997; 119(25): 5818-27.
    • (1997) J Am Chem Soc , vol.119 , Issue.25 , pp. 5818-5827
    • Hajduk, P.J.1    Sheppard, G.2    Nettesheim, D.G.3
  • 53
    • 0037011911 scopus 로고    scopus 로고
    • Phenoxyphenyl sulfone Nformylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors
    • Wada CK, Holms JH, Curtin ML, et al. Phenoxyphenyl sulfone Nformylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 2002; 45(1): 219-32.
    • (2002) J Med Chem , vol.45 , Issue.1 , pp. 219-232
    • Wada, C.K.1    Holms, J.H.2    Curtin, M.L.3
  • 54
    • 33750689843 scopus 로고    scopus 로고
    • Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity
    • Qu X, Yuan Y, Xu W, et al. Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. Anticancer Res 2006; 26(5A): 3573-8.
    • (2006) Anticancer Res , vol.26 , Issue.5 A , pp. 3573-3578
    • Qu, X.1    Yuan, Y.2    Xu, W.3
  • 55
    • 43749091066 scopus 로고    scopus 로고
    • Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors
    • Cheng XC, Wang Q, Fang H, Tang W, Xu WF. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem 2008; 16(10): 5398-404.
    • (2008) Bioorg Med Chem , vol.16 , Issue.10 , pp. 5398-5404
    • Cheng, X.C.1    Wang, Q.2    Fang, H.3    Tang, W.4    Xu, W.F.5
  • 56
    • 84863270811 scopus 로고    scopus 로고
    • Design of barbituratenitrate hybrids that inhibit MMP-9 activity and secretion
    • Just Accepted Manuscript, DOI: 10.1021/jm201352k
    • Wang J, S'Sullivan S, Harmon S, et al. Design of barbituratenitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem 2012; Just Accepted Manuscript, DOI: 10.1021/jm201352k
    • (2012) J Med Chem
    • Wang, J.1    S'Sullivan, S.2    Harmon, S.3
  • 57
    • 79961173981 scopus 로고    scopus 로고
    • N-substituted homopiperazine barbiturates as gelatinase inhibitors
    • Wang J, Medina C, Radomski MW, Gilmer JF. N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorg Med Chem 2011; 19(16): 4985-99.
    • (2011) Bioorg Med Chem , vol.19 , Issue.16 , pp. 4985-4999
    • Wang, J.1    Medina, C.2    Radomski, M.W.3    Gilmer, J.F.4
  • 58
    • 51849144056 scopus 로고    scopus 로고
    • Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity
    • Ledour G, Moroy G, Rouffet M, et al. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg Med Chem 2008; 16(18): 8745-59.
    • (2008) Bioorg Med Chem , vol.16 , Issue.18 , pp. 8745-8759
    • Ledour, G.1    Moroy, G.2    Rouffet, M.3
  • 59
    • 62749157590 scopus 로고    scopus 로고
    • Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors
    • Rubino MT, Agamennone M, Campestre C, et al. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. ChemMedChem 2009; 4(3): 352-62.
    • (2009) ChemMedChem , vol.4 , Issue.3 , pp. 352-362
    • Rubino, M.T.1    Agamennone, M.2    Campestre, C.3
  • 60
    • 22144461050 scopus 로고    scopus 로고
    • Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A
    • Ikejiri M, Bernardo MM, Meroueh SO, et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005; 70(14): 5709-12.
    • (2005) J Org Chem , vol.70 , Issue.14 , pp. 5709-5712
    • Ikejiri, M.1    Bernardo, M.M.2    Meroueh, S.O.3
  • 61
    • 79951531008 scopus 로고    scopus 로고
    • Sulfonate-containing thiiranes as selective gelatinase inhibitors
    • Testero SA, Lee M, Staran RT, et al. Sulfonate-containing thiiranes as selective gelatinase inhibitors. ACS Med Chem Lett 2011; 2: 177-81.
    • (2011) ACS Med Chem Lett , vol.2 , pp. 177-181
    • Testero, S.A.1    Lee, M.2    Staran, R.T.3
  • 62
    • 79955150446 scopus 로고    scopus 로고
    • Exploring the functional space of thiiranes as gelatinase inhibitors using click chemistry
    • Testero SA, Llarrull LI, Fisher JF, Chang M, Mobashery S. Exploring the functional space of thiiranes as gelatinase inhibitors using click chemistry. ARKIVOC 2011; 7: 221-36.
    • (2011) ARKIVOC , vol.7 , pp. 221-236
    • Testero, S.A.1    Llarrull, L.I.2    Fisher, J.F.3    Chang, M.4    Mobashery, S.5
  • 63
    • 0034686685 scopus 로고    scopus 로고
    • Potent and selective mechanism-based inhibition of gelatinases
    • Brown S, Bernardo M, Li ZH, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000; 122: 6799-800.
    • (2000) J Am Chem Soc , vol.122 , pp. 6799-6800
    • Brown, S.1    Bernardo, M.2    Li, Z.H.3
  • 64
    • 79961234156 scopus 로고    scopus 로고
    • Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities
    • Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem 2011; 54(15): 5532-9.
    • (2011) J Med Chem , vol.54 , Issue.15 , pp. 5532-5539
    • Zhang, Y.1    Fang, H.2    Feng, J.3    Jia, Y.4    Wang, X.5    Xu, W.6
  • 65
    • 58149086406 scopus 로고    scopus 로고
    • Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: Iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates
    • Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates. J Med Chem 2008; 51(24): 7968-79.
    • (2008) J Med Chem , vol.51 , Issue.24 , pp. 7968-7979
    • Marques, S.M.1    Nuti, E.2    Rossello, A.3
  • 66
    • 39749190017 scopus 로고    scopus 로고
    • Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes
    • Zhu Z, Mazzola R, Sinning L, et al. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes. J Med Chem 2008; 51(4): 725-36.
    • (2008) J Med Chem , vol.51 , Issue.4 , pp. 725-736
    • Zhu, Z.1    Mazzola, R.2    Sinning, L.3
  • 67
    • 34548670257 scopus 로고    scopus 로고
    • Crystal structures of MMP-9 complexes with five inhibitors: Contribution of the flexible Arg424 side-chain to selectivity
    • Tochowicz A. Maskos K, Huber R, et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 2007; 371: 989-1006.
    • (2007) J Mol Biol , vol.371 , pp. 989-1006
    • Tochowicz, A.1    Maskos, K.2    Huber, R.3
  • 68
    • 2542448200 scopus 로고    scopus 로고
    • Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2
    • Zhang W, Hou TJ, Qiao XB, Huai S, Xu XJ. Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2. J Mol Model 2004; 10: 112-20.
    • (2004) J Mol Model , vol.10 , pp. 112-120
    • Zhang, W.1    Hou, T.J.2    Qiao, X.B.3    Huai, S.4    Xu, X.J.5
  • 69
    • 23644438889 scopus 로고    scopus 로고
    • A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors
    • Gupta SP, Kumaran S. A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors. Bioorg Med Chem 2005; 13: 5454-62.
    • (2005) Bioorg Med Chem , vol.13 , pp. 5454-5462
    • Gupta, S.P.1    Kumaran, S.2
  • 70
    • 0037401628 scopus 로고    scopus 로고
    • Quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines
    • Gupta SP, Kumar D, Kumaran SA. Quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. Bioorg Med Chem 2003; 11: 1975-81.
    • (2003) Bioorg Med Chem , vol.11 , pp. 1975-1981
    • Gupta, S.P.1    Kumar, D.2    Kumaran, S.A.3
  • 71
    • 49149123555 scopus 로고    scopus 로고
    • Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors
    • Tuccinardi T, Nuti E, Ortore G, Rossello A, Avramova SI, Martinelli A. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Bioorg Med Chem 2008; 16(16): 7749-58.
    • (2008) Bioorg Med Chem , vol.16 , Issue.16 , pp. 7749-7758
    • Tuccinardi, T.1    Nuti, E.2    Ortore, G.3    Rossello, A.4    Avramova, S.I.5    Martinelli, A.6
  • 72
    • 68149149512 scopus 로고    scopus 로고
    • Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors
    • Tuccinardi T, Ortore G, Santos MA, et al. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors. J Chem Inf Model 2009; 49(7): 1715-24.
    • (2009) J Chem Inf Model , vol.49 , Issue.7 , pp. 1715-1724
    • Tuccinardi, T.1    Ortore, G.2    Santos, M.A.3
  • 73
    • 77149131528 scopus 로고    scopus 로고
    • To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition
    • Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010; 1803(1): 72-94.
    • (2010) Biochim Biophys Acta , vol.1803 , Issue.1 , pp. 72-94
    • Jacobsen, J.A.1    Major Jourden, J.L.2    Miller, M.T.3    Cohen, S.M.4
  • 74
    • 18444397733 scopus 로고    scopus 로고
    • Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor
    • Roswell S, Hawtin P, Minshull CA, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002; 319: 173-81.
    • (2002) J Mol Biol , vol.319 , pp. 173-181
    • Roswell, S.1    Hawtin, P.2    Minshull, C.A.3
  • 76
    • 79959230769 scopus 로고    scopus 로고
    • The impact of ionization states of matrix metalloproteinase inhibitors on docking-based inhibitor design
    • Zhong H, Wees MA, Faure TD, Carrillo C, Arbiser J, Bowen JP. The impact of ionization states of matrix metalloproteinase inhibitors on docking-based inhibitor design. ACS Med Chem Lett 2011; 2: 455-460.
    • (2011) ACS Med Chem Lett , vol.2 , pp. 455-460
    • Zhong, H.1    Wees, M.A.2    Faure, T.D.3    Carrillo, C.4    Arbiser, J.5    Bowen, J.P.6
  • 77
    • 34248596450 scopus 로고    scopus 로고
    • Computational protocol for predicting the binding affinities of zinc containing metalloprotein-ligand complexes
    • Jain T, Jayaram B. Computational protocol for predicting the binding affinities of zinc containing metalloprotein-ligand complexes. Proteins: Struct Funct Bioinfo 2007; 67: 1167-78.
    • (2007) Proteins: Struct Funct Bioinfo , vol.67 , pp. 1167-1178
    • Jain, T.1    Jayaram, B.2
  • 78
    • 50249107450 scopus 로고    scopus 로고
    • Peptide hydrolysis catalyzed by matrix metalloprotein 2: A computational study
    • Díaz N, Suárez D. Peptide hydrolysis catalyzed by matrix metalloprotein 2: A computational study. J Phys Chem B 2008; 112: 8412-24.
    • (2008) J Phys Chem B , vol.112 , pp. 8412-8424
    • Díaz, N.1    Suárez, D.2
  • 79
    • 78149451538 scopus 로고    scopus 로고
    • QM/MM studies of the matrix metalloproteinase 2 (MMP2) inhibition mechanism of (S)-SB-3CT and its oxirane analogue
    • Zhou J, Tao P, Fisher JF, Shi Q, Mobashery S, Schlegel HB. QM/MM studies of the matrix metalloproteinase 2 (MMP2) inhibition mechanism of (S)-SB-3CT and its oxirane analogue. J Chem Theory Comput 2010; 6: 3580-7.
    • (2010) J Chem Theory Comput , vol.6 , pp. 3580-3587
    • Zhou, J.1    Tao, P.2    Fisher, J.F.3    Shi, Q.4    Mobashery, S.5    Schlegel, H.B.6
  • 80
    • 79957706173 scopus 로고    scopus 로고
    • Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression
    • Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev 2011; 22(2): 73-81.
    • (2011) Cytokine Growth Factor Rev , vol.22 , Issue.2 , pp. 73-81
    • Dejonckheere, E.1    Vandenbroucke, R.E.2    Libert, C.3
  • 81
    • 67349212939 scopus 로고    scopus 로고
    • Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological lung tissue remodeling?
    • Garbacki N, Di Valentin E, Piette J, Cataldo D, Crahay C, Colige A. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009; 22(4): 267-78.
    • (2009) Pulm Pharmacol Ther , vol.22 , Issue.4 , pp. 267-278
    • Garbacki, N.1    Di Valentin, E.2    Piette, J.3    Cataldo, D.4    Crahay, C.5    Colige, A.6
  • 82


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.